Jen-Sing Liu

Title: Innovations of Jen-Sing Liu in Immunotherapy

Introduction

Jen-Sing Liu is an accomplished inventor based in Austin, TX (US). He is known for his significant contributions to the field of immunotherapy, particularly through his innovative patent related to bispecific immunoglobulins. His work aims to enhance the targeted killing of cancer cells by utilizing the body's immune system.

Latest Patents

One of Jen-Sing Liu's notable patents is the Bispecific scFv immunofusion (BIf). This invention is designed to bind to specific cell surface molecules on target cells, such as cancer cells, and immune effector cells, like cytotoxic T lymphocytes. The BIf is a polypeptide that includes a first target binding domain for cancer cells, a second effector binding domain for immunologic effectors, and an immunoglobulin constant region linker that connects the two binding domains. This innovative approach has the potential to improve cancer treatment outcomes significantly.

Career Highlights

Throughout his career, Jen-Sing Liu has worked with reputable organizations, including Scott & White Healthcare and Aptevo Research and Development LLC. His experience in these institutions has allowed him to develop and refine his groundbreaking ideas in immunotherapy.

Collaborations

Jen-Sing Liu has collaborated with various professionals in his field, including his coworker Shu-Ru Kuo, who has contributed to his research endeavors.

Conclusion

Jen-Sing Liu's innovative work in bispecific immunoglobulins represents a significant advancement in cancer treatment. His dedication to improving immunotherapy continues to inspire future research and development in the field.